Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 13, 2020 09:15 ET | Source: CicloMed LLC

CicloMed Presents New Oncology Data from Phase I Trial with Fosciclopirox at 2020 ASCO Genitourinary Cancers Symposium

First-time results from recently completed fosciclopirox Phase I safety, dose tolerance, pharmacokinetics and pharmacodynamics trial in advanced solid-tumor patientsInitiation of fosciclopirox...
December 03, 2019 09:30 ET | Source: CicloMed LLC

CicloMed Expands Fosciclopirox Phase 1 Trial to Include Cisplatin-Ineligible Muscle-Invasive Bladder Cancer Patients

KANSAS CITY, Mo., Dec. 03, 2019 (GLOBE NEWSWIRE) -- CicloMed LLC, a biotechnology company developing novel treatments for bladder cancer, today announced the expansion of its fosciclopirox clinical...
May 31, 2018 09:30 ET | Source: CicloMed LLC

CicloMed Announces ASCO 2018 Presentation on Clinical Trial for Ciclopirox Prodrug, Under Development for Bladder Cancer

KANSAS CITY, Mo., May 31, 2018 (GLOBE NEWSWIRE) -- CicloMed LLC, a biotechnology company developing novel treatments for bladder cancer, today announced the presentation of a scientific poster...
April 12, 2018 09:00 ET | Source: CicloMed LLC

CicloMed Announces Presentation of Preclinical Evidence for its Bladder Cancer Agent at AACR 2018 Meeting

KANSAS CITY, Mo., April 12, 2018 (GLOBE NEWSWIRE) -- CicloMed LLC, a biotechnology company developing novel treatments for bladder cancer, today announced the presentation of preclinical evidence...
February 28, 2018 10:08 ET | Source: CicloMed LLC

CicloMed Announces First Patient Dosed with Ciclopirox Prodrug in Phase I Trial in Patients with Advanced Solid Tumors

KANSAS CITY, Mo., Feb. 28, 2018 (GLOBE NEWSWIRE) -- CicloMed LLC, a biotechnology company developing novel treatments for bladder cancer, today announced that the first patient has been dosed in a...
October 11, 2017 09:00 ET | Source: CicloMed LLC

CicloMed Announces FDA Clearance of IND Application for Ciclopirox Prodrug in the Treatment of Bladder Cancer

KANSAS CITY, Mo., Oct. 11, 2017 (GLOBE NEWSWIRE) -- CicloMed LLC announced today that its development candidate for non-muscle-invasive and muscle-invasive bladder cancer, Ciclopirox Prodrug, was...